Latest From Apotex Inc.
Servier’s Canadian perindopril arginine salt patent is invalid for being obvious and for having patent claims wider in scope than the invention.
Strides Pharma is “very confident” about future after the Indian company’s fourth-quarter US revenues rocketed by 181% and EBITDA margins beat market expectations.
Several aspects of the FDA’s draft guidance on the pathway for competitive generic therapies require clarification, according to detailed feedback submitted by industry.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Apotex Inc.
- Senior Management
- Jeremy B Desai, PhD, Pres. & CEO
- Contact Info
Phone: (800) 268-4623
150 Signet Dr.
Toronto, M9L IT9
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.